169 related articles for article (PubMed ID: 34992346)
1. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.
Bae S; Kwon J; Lee SB; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():5099-5108. PubMed ID: 34992346
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole.
Bae S; Kwon J; Lee MH; Yu KS; Lee S
Drug Des Devel Ther; 2023; 17():497-506. PubMed ID: 36814893
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.
Kim HC; Yang E; Ban MS; Kim YK; Hong SH; Jung J; Jang IJ; Lee S
Drug Des Devel Ther; 2023; 17():1115-1124. PubMed ID: 37077412
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.
Jing S; Zhu Y; Liu W; Yang K; Hu L; Deng D; Lu C; Lin Y
Adv Ther; 2021 Mar; 38(3):1660-1676. PubMed ID: 33575950
[TBL] [Abstract][Full Text] [Related]
7. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
[TBL] [Abstract][Full Text] [Related]
8. The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.
Kim D; Park MS; Yoo BW; Hong T; Park SJ; Kim CO
Drug Des Devel Ther; 2019; 13():3151-3159. PubMed ID: 31564831
[TBL] [Abstract][Full Text] [Related]
9. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
10. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
Yi S; Lee H; Jang SB; Byun HM; Yoon SH; Cho JY; Jang IJ; Yu KS
Aliment Pharmacol Ther; 2017 Aug; 46(3):337-346. PubMed ID: 28543183
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
12. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
Iida H; Inamori M; Okuno K; Sekino Y; Sakai E; Okubo H; Higurashi T; Endo H; Hosono K; Yoneda M; Koide T; Takahashi H; Goto A; Kubota K; Saito S; Maeda S; Nakajima A; Gotoh E
Hepatogastroenterology; 2015; 62(138):493-6. PubMed ID: 25916088
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic comparison study of a combination containing 500 mg of Naproxen and 20 mg of Esomeprazole: a randomized, single-dose, 2-way crossover, open-label study in healthy Korean men.
Choi HG; Jeon JY; Kwak SS; Kim H; Jin C; Im YJ; Kim EY; Wang HM; Kim Y; Lee SY; Kim MG
Clin Ther; 2015 Jan; 37(1):83-93. PubMed ID: 25482305
[TBL] [Abstract][Full Text] [Related]
14. Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression.
Furuta K; Adachi K; Aimi M; Shimura S; Mikami H; Nishimura N; Ishimura N; Ishihara S; Naora K; Kinoshita Y
Digestion; 2016; 93(2):111-20. PubMed ID: 26637113
[TBL] [Abstract][Full Text] [Related]
15. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
Wang H; Shao F; Liu X; Xu W; Ou N; Qin X; Liu F; Hou X; Hu H; Jiang J
Br J Clin Pharmacol; 2019 Nov; 85(11):2547-2558. PubMed ID: 31332820
[TBL] [Abstract][Full Text] [Related]
17. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
[TBL] [Abstract][Full Text] [Related]
18. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26121346
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of YYD601, a Dual Delayed-Release Formulation of Esomeprazole, Following Single and Multiple Doses in Healthy Adult Volunteers Under Fasting and Fed Conditions.
Lee HW; Kang WY; Jung W; Gwon MR; Cho K; Yoon YR; Seong SJ
Drug Des Devel Ther; 2022; 16():619-634. PubMed ID: 35281316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
